The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
The Food and Drug Administration on Thursday approved Amgen's treatment for patients with the most deadly form of lung cancer. The agency cleared the drug, called Imdelltra, as a second or later ...
May 16 (Reuters) - (This May 16 story has been officially corrected by Amgen to change the pricing estimate in paragraph 4) The U.S. Food and Drug Administration on Thursday granted accelerated ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who ...
SOURCE: U.S. Food and Drug Administration, news release, May 16, 2024; Amgen, news release, May 16, 2024; New York Times What This Means For You The FDA has approved a new drug to treat a tough ...
Two major potential blockbuster products, Roche’s multiple sclerosis drug Ocrevus and Sanofi and Regeneron's Dupixent for eczema, have gained FDA approval. Analysts Evaluate Pharma have ...
Dyax and Merck/Santarus get FDA approvals. The U.S. Food and Drug Administration approved two drugs Tuesday night -- a prescription drug for a rare, genetic disorder and an over-the-counter ...